|
gptkbp:instanceOf
|
gptkb:Dragon
gptkb:chemical_compound
|
|
gptkbp:CASNumber
|
23007-85-4
|
|
gptkbp:category
|
neurotoxins
dopaminergic neurotoxins
tetrahydropyridines
|
|
gptkbp:chemicalFormula
|
C12H15N
|
|
gptkbp:discoveredIn
|
1970s
|
|
gptkbp:firstReported
|
Barry Kidston
|
|
gptkbp:hasInChIKey
|
RZJHPPFJUXUBQB-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN1CCC=C(C1)C2=CC=CC=C2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MPTP
|
|
gptkbp:IUPACName
|
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
|
|
gptkbp:knownFor
|
causing parkinsonism in humans
|
|
gptkbp:mechanismOfAction
|
selective destruction of dopaminergic neurons
|
|
gptkbp:meltingPoint
|
37–39 °C
|
|
gptkbp:MeSH_ID
|
D015242
|
|
gptkbp:metabolism
|
MAO-B (monoamine oxidase B)
|
|
gptkbp:molecularWeight
|
173.25 g/mol
|
|
gptkbp:notableEvent
|
1982 California synthetic heroin case
|
|
gptkbp:notUsedAs
|
therapeutic drug
|
|
gptkbp:predecessor
|
MPP+
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1231
4167
4316
|
|
gptkbp:relatedTo
|
gptkb:Parkinson's_disease
|
|
gptkbp:riskFactor
|
highly toxic
|
|
gptkbp:routeOfExposure
|
oral
inhalation
intravenous
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:toxicity
|
neurotoxic
|
|
gptkbp:UNII
|
3OWP7A1K6S
|
|
gptkbp:usedIn
|
animal models of Parkinson's disease
|
|
gptkbp:bfsParent
|
gptkb:SSR-481
|
|
gptkbp:bfsLayer
|
6
|